pharma · Obesity · Obesity With Diabetes · KLRA
Kailera Therapeutics
NovaPharmaNews editorial coverage mentioning Kailera Therapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2024
- Employees
- 153
- Programs
- 7
- Drugs
- 3
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Kailera Therapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Kailera Therapeutics — regulatory, clinical, and market analysis.
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.
Kailera's Triple-G Drug: A Potential Game-Changer in Pharma
Kailera's triple-G drug showed powerful efficacy in early trials announced May 27, 2026. This catalyst analysis outlines implications for pharma business development, regulatory teams, and investors.